Evaluating the role of corticosteroid pulse therapy in patients with secondary progressive multiple sclerosis receiving mitoxantrone : a double blind randomized controlled clinical trial

Background: Multiple sclerosis (MS) is a central nervous system disorder with periods of recurrence and recovery. Mitoxantrone has been approved for secondary progressive MS (SPMS) treatment but data lacks the role of corticosteroid pulse therapy in SPMS. Objectives: To evaluate the role of corticos...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Iranian red crescent medical journal 2015-10, Vol.17 (10), p.1-6
Hauptverfasser: Rahimdil, Abu al-Qasim, Mellat, Ali, Zaynali, Ahmad
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 6
container_issue 10
container_start_page 1
container_title Iranian red crescent medical journal
container_volume 17
creator Rahimdil, Abu al-Qasim
Mellat, Ali
Zaynali, Ahmad
description Background: Multiple sclerosis (MS) is a central nervous system disorder with periods of recurrence and recovery. Mitoxantrone has been approved for secondary progressive MS (SPMS) treatment but data lacks the role of corticosteroid pulse therapy in SPMS. Objectives: To evaluate the role of corticosteroid pulse therapy in patients with SPMS receiving mitoxantrone. Patients and Methods: A double blind randomized controlled clinical trial was performed on 71 patients with SPMS referred to Shahid Sadoughi Hospital (Yazd, Iran) for receiving mitoxantrone in two groups. The first group (35 patients) received 20 mg mitoxantrone plus 500 mg methylprednisolone monthly for six months. The second group (36 patients) received the same dosage of mitoxantrone plus 100 CC of 5% dextrose water monthly for six months. Expanded disability status scale (EDSS), MRI plaques in both groups before and after the treatment completion and six months after the end of trial were compared together. Results: 28 men and 43 women enrolled in the study. MRI plaques number reduced in groups significantly (2.29 vs. 2.17) without significant difference between the groups (P = 0.782). Six months after trial completion, plaques number increased in groups without significantly difference (0.72 vs. 0.77, P = 0.611). The mean value of EDSS showed significant reduction at the end of treatment in groups (0.79 and 0.53) without significant difference between the groups (P = 0.953). Six months after trial completion, EDSS increased in groups without significant difference (0.35 vs. 0.43, P = 0.624). Conclusions: Corticosteroid pulse therapy in SPMS was effective in inflammatory process, but could not postpone or decline the neurodegenerative process and besides the imposing side effects could not result in significant improvement in EDSS and MRI plaques number in long term.
doi_str_mv 10.5812/ircmj.30618
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4636858</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1733193041</sourcerecordid><originalsourceid>FETCH-LOGICAL-c403t-b9d62fef5c520caa0ee18068447421d035c638e6bb58a5d5048d01f07ac3878d3</originalsourceid><addsrcrecordid>eNpVkctu1DAUhiNERS-wYg3yEqmaYseXeFggoapApUrdwNpy7JMZV44dbGegPBpPh9MpI7ry0Tmf_3P5m-Y1wRdckva9S2a8u6BYEPmsOWlxx1ak5p8fYsyOm9Oc7zDma9HSF81xK7gQjLOT5s_VTvtZFxc2qGwBpegBxQGZmIozMRdI0Vk0zT7DAiQ93SMX0FS_QCgZ_XRlizKYGKxO92hKcZMgZ7cDNM6-uKnqZeOrTHYZJTDgdkuz0ZX4S4eSYgD0AWlk49xXtvcuWJR0sHF0v8HWSRbI-yWsNWe0RyU57V82R4OuY716fM-a75-vvl1-Xd3cfrm-_HSzMgzTsurXVrQDDNzwFhutMUA9iZCMdawlFlNuBJUg-p5LzS3HTFpMBtxpQ2UnLT1rPu51p7kfwZq6dtJeTcmNdWMVtVNPK8Ft1SbuFBNUSC6rwLtHgRR_zJCLGl024L0OEOesSEcpWVPMSEXP96ip98oJhkMbgtXitnpwWz24Xem3_092YP_ZW4E3ewBqHgZ9IES7JrSjfwFARbfA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1733193041</pqid></control><display><type>article</type><title>Evaluating the role of corticosteroid pulse therapy in patients with secondary progressive multiple sclerosis receiving mitoxantrone : a double blind randomized controlled clinical trial</title><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Rahimdil, Abu al-Qasim ; Mellat, Ali ; Zaynali, Ahmad</creator><creatorcontrib>Rahimdil, Abu al-Qasim ; Mellat, Ali ; Zaynali, Ahmad</creatorcontrib><description>Background: Multiple sclerosis (MS) is a central nervous system disorder with periods of recurrence and recovery. Mitoxantrone has been approved for secondary progressive MS (SPMS) treatment but data lacks the role of corticosteroid pulse therapy in SPMS. Objectives: To evaluate the role of corticosteroid pulse therapy in patients with SPMS receiving mitoxantrone. Patients and Methods: A double blind randomized controlled clinical trial was performed on 71 patients with SPMS referred to Shahid Sadoughi Hospital (Yazd, Iran) for receiving mitoxantrone in two groups. The first group (35 patients) received 20 mg mitoxantrone plus 500 mg methylprednisolone monthly for six months. The second group (36 patients) received the same dosage of mitoxantrone plus 100 CC of 5% dextrose water monthly for six months. Expanded disability status scale (EDSS), MRI plaques in both groups before and after the treatment completion and six months after the end of trial were compared together. Results: 28 men and 43 women enrolled in the study. MRI plaques number reduced in groups significantly (2.29 vs. 2.17) without significant difference between the groups (P = 0.782). Six months after trial completion, plaques number increased in groups without significantly difference (0.72 vs. 0.77, P = 0.611). The mean value of EDSS showed significant reduction at the end of treatment in groups (0.79 and 0.53) without significant difference between the groups (P = 0.953). Six months after trial completion, EDSS increased in groups without significant difference (0.35 vs. 0.43, P = 0.624). Conclusions: Corticosteroid pulse therapy in SPMS was effective in inflammatory process, but could not postpone or decline the neurodegenerative process and besides the imposing side effects could not result in significant improvement in EDSS and MRI plaques number in long term.</description><identifier>ISSN: 2074-1804</identifier><identifier>EISSN: 2074-1812</identifier><identifier>DOI: 10.5812/ircmj.30618</identifier><identifier>PMID: 26566454</identifier><language>eng</language><publisher>Dubai, United Arab Emirates: Iranian Hospital</publisher><subject>Adrenocortical hormones ; Mitoxantrone ; Multiple sclerosis ; Therapeutic use ; Treatment ; هرمونات قشرة الغدة الكظرية</subject><ispartof>Iranian red crescent medical journal, 2015-10, Vol.17 (10), p.1-6</ispartof><rights>Copyright © 2015, Iranian Red Crescent Medical Journal. 2015</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c403t-b9d62fef5c520caa0ee18068447421d035c638e6bb58a5d5048d01f07ac3878d3</citedby><cites>FETCH-LOGICAL-c403t-b9d62fef5c520caa0ee18068447421d035c638e6bb58a5d5048d01f07ac3878d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4636858/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4636858/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,729,782,786,887,27931,27932,53798,53800</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26566454$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rahimdil, Abu al-Qasim</creatorcontrib><creatorcontrib>Mellat, Ali</creatorcontrib><creatorcontrib>Zaynali, Ahmad</creatorcontrib><title>Evaluating the role of corticosteroid pulse therapy in patients with secondary progressive multiple sclerosis receiving mitoxantrone : a double blind randomized controlled clinical trial</title><title>Iranian red crescent medical journal</title><addtitle>Iran Red Crescent Med J</addtitle><description>Background: Multiple sclerosis (MS) is a central nervous system disorder with periods of recurrence and recovery. Mitoxantrone has been approved for secondary progressive MS (SPMS) treatment but data lacks the role of corticosteroid pulse therapy in SPMS. Objectives: To evaluate the role of corticosteroid pulse therapy in patients with SPMS receiving mitoxantrone. Patients and Methods: A double blind randomized controlled clinical trial was performed on 71 patients with SPMS referred to Shahid Sadoughi Hospital (Yazd, Iran) for receiving mitoxantrone in two groups. The first group (35 patients) received 20 mg mitoxantrone plus 500 mg methylprednisolone monthly for six months. The second group (36 patients) received the same dosage of mitoxantrone plus 100 CC of 5% dextrose water monthly for six months. Expanded disability status scale (EDSS), MRI plaques in both groups before and after the treatment completion and six months after the end of trial were compared together. Results: 28 men and 43 women enrolled in the study. MRI plaques number reduced in groups significantly (2.29 vs. 2.17) without significant difference between the groups (P = 0.782). Six months after trial completion, plaques number increased in groups without significantly difference (0.72 vs. 0.77, P = 0.611). The mean value of EDSS showed significant reduction at the end of treatment in groups (0.79 and 0.53) without significant difference between the groups (P = 0.953). Six months after trial completion, EDSS increased in groups without significant difference (0.35 vs. 0.43, P = 0.624). Conclusions: Corticosteroid pulse therapy in SPMS was effective in inflammatory process, but could not postpone or decline the neurodegenerative process and besides the imposing side effects could not result in significant improvement in EDSS and MRI plaques number in long term.</description><subject>Adrenocortical hormones</subject><subject>Mitoxantrone</subject><subject>Multiple sclerosis</subject><subject>Therapeutic use</subject><subject>Treatment</subject><subject>هرمونات قشرة الغدة الكظرية</subject><issn>2074-1804</issn><issn>2074-1812</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNpVkctu1DAUhiNERS-wYg3yEqmaYseXeFggoapApUrdwNpy7JMZV44dbGegPBpPh9MpI7ry0Tmf_3P5m-Y1wRdckva9S2a8u6BYEPmsOWlxx1ak5p8fYsyOm9Oc7zDma9HSF81xK7gQjLOT5s_VTvtZFxc2qGwBpegBxQGZmIozMRdI0Vk0zT7DAiQ93SMX0FS_QCgZ_XRlizKYGKxO92hKcZMgZ7cDNM6-uKnqZeOrTHYZJTDgdkuz0ZX4S4eSYgD0AWlk49xXtvcuWJR0sHF0v8HWSRbI-yWsNWe0RyU57V82R4OuY716fM-a75-vvl1-Xd3cfrm-_HSzMgzTsurXVrQDDNzwFhutMUA9iZCMdawlFlNuBJUg-p5LzS3HTFpMBtxpQ2UnLT1rPu51p7kfwZq6dtJeTcmNdWMVtVNPK8Ft1SbuFBNUSC6rwLtHgRR_zJCLGl024L0OEOesSEcpWVPMSEXP96ip98oJhkMbgtXitnpwWz24Xem3_092YP_ZW4E3ewBqHgZ9IES7JrSjfwFARbfA</recordid><startdate>20151001</startdate><enddate>20151001</enddate><creator>Rahimdil, Abu al-Qasim</creator><creator>Mellat, Ali</creator><creator>Zaynali, Ahmad</creator><general>Iranian Hospital</general><general>Kowsar</general><scope>AACQA</scope><scope>ADJCN</scope><scope>AEION</scope><scope>AHFXO</scope><scope>AHHHR</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20151001</creationdate><title>Evaluating the role of corticosteroid pulse therapy in patients with secondary progressive multiple sclerosis receiving mitoxantrone : a double blind randomized controlled clinical trial</title><author>Rahimdil, Abu al-Qasim ; Mellat, Ali ; Zaynali, Ahmad</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c403t-b9d62fef5c520caa0ee18068447421d035c638e6bb58a5d5048d01f07ac3878d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adrenocortical hormones</topic><topic>Mitoxantrone</topic><topic>Multiple sclerosis</topic><topic>Therapeutic use</topic><topic>Treatment</topic><topic>هرمونات قشرة الغدة الكظرية</topic><toplevel>online_resources</toplevel><creatorcontrib>Rahimdil, Abu al-Qasim</creatorcontrib><creatorcontrib>Mellat, Ali</creatorcontrib><creatorcontrib>Zaynali, Ahmad</creatorcontrib><collection>بنك معلومات "معرفة" لدراسات العلوم العسكرية والأمنية - e-Marefa Military &amp; Security Database</collection><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>مجلس التعاون الخليجي وإيران - e-Marefa The GCC-Iranian Affairs</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>دراسات الشرق الأوسط - e-Marefa Middle Eastern Studies</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Iranian red crescent medical journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rahimdil, Abu al-Qasim</au><au>Mellat, Ali</au><au>Zaynali, Ahmad</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluating the role of corticosteroid pulse therapy in patients with secondary progressive multiple sclerosis receiving mitoxantrone : a double blind randomized controlled clinical trial</atitle><jtitle>Iranian red crescent medical journal</jtitle><addtitle>Iran Red Crescent Med J</addtitle><date>2015-10-01</date><risdate>2015</risdate><volume>17</volume><issue>10</issue><spage>1</spage><epage>6</epage><pages>1-6</pages><issn>2074-1804</issn><eissn>2074-1812</eissn><abstract>Background: Multiple sclerosis (MS) is a central nervous system disorder with periods of recurrence and recovery. Mitoxantrone has been approved for secondary progressive MS (SPMS) treatment but data lacks the role of corticosteroid pulse therapy in SPMS. Objectives: To evaluate the role of corticosteroid pulse therapy in patients with SPMS receiving mitoxantrone. Patients and Methods: A double blind randomized controlled clinical trial was performed on 71 patients with SPMS referred to Shahid Sadoughi Hospital (Yazd, Iran) for receiving mitoxantrone in two groups. The first group (35 patients) received 20 mg mitoxantrone plus 500 mg methylprednisolone monthly for six months. The second group (36 patients) received the same dosage of mitoxantrone plus 100 CC of 5% dextrose water monthly for six months. Expanded disability status scale (EDSS), MRI plaques in both groups before and after the treatment completion and six months after the end of trial were compared together. Results: 28 men and 43 women enrolled in the study. MRI plaques number reduced in groups significantly (2.29 vs. 2.17) without significant difference between the groups (P = 0.782). Six months after trial completion, plaques number increased in groups without significantly difference (0.72 vs. 0.77, P = 0.611). The mean value of EDSS showed significant reduction at the end of treatment in groups (0.79 and 0.53) without significant difference between the groups (P = 0.953). Six months after trial completion, EDSS increased in groups without significant difference (0.35 vs. 0.43, P = 0.624). Conclusions: Corticosteroid pulse therapy in SPMS was effective in inflammatory process, but could not postpone or decline the neurodegenerative process and besides the imposing side effects could not result in significant improvement in EDSS and MRI plaques number in long term.</abstract><cop>Dubai, United Arab Emirates</cop><pub>Iranian Hospital</pub><pmid>26566454</pmid><doi>10.5812/ircmj.30618</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2074-1804
ispartof Iranian red crescent medical journal, 2015-10, Vol.17 (10), p.1-6
issn 2074-1804
2074-1812
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4636858
source PubMed Central Open Access; PubMed Central
subjects Adrenocortical hormones
Mitoxantrone
Multiple sclerosis
Therapeutic use
Treatment
هرمونات قشرة الغدة الكظرية
title Evaluating the role of corticosteroid pulse therapy in patients with secondary progressive multiple sclerosis receiving mitoxantrone : a double blind randomized controlled clinical trial
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T22%3A54%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluating%20the%20role%20of%20corticosteroid%20pulse%20therapy%20in%20patients%20with%20secondary%20progressive%20multiple%20sclerosis%20receiving%20mitoxantrone%20:%20a%20double%20blind%20randomized%20controlled%20clinical%20trial&rft.jtitle=Iranian%20red%20crescent%20medical%20journal&rft.au=Rahimdil,%20Abu%20al-Qasim&rft.date=2015-10-01&rft.volume=17&rft.issue=10&rft.spage=1&rft.epage=6&rft.pages=1-6&rft.issn=2074-1804&rft.eissn=2074-1812&rft_id=info:doi/10.5812/ircmj.30618&rft_dat=%3Cproquest_pubme%3E1733193041%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1733193041&rft_id=info:pmid/26566454&rfr_iscdi=true